Biomarkers and exposure to asbestos;Marqueurs biologiques et exposition a l'amiante

Revue des Maladies Respiratoires

Volumn 16, Issue 6 BIS, 1999, Pages 1236-1243

  Pairon, J C ^a   Housset, B ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

Asbestos; Glutathione S transferase; Molecular markers

Indexed keywords

BIOCHEMICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOCHROME P450; CYTOKERATIN 19 FRAGMENT; GLUTATHIONE TRANSFERASE; PROTEIN P21;

ANTIBODY DETECTION; ASBESTOSIS; CANCER SCREENING; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; HUMAN; LUNG CANCER; OCCUPATIONAL EXPOSURE; ONCOGENE K RAS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ASBESTOSIS; BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; ENVIRONMENTAL EXPOSURE; HUMANS;

EID: 0033398137     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (92)

1. LESUR O, BERNARD AM, BEGIN RO : Clara cell protein (CC-16) and surfactant-associated protein A (SP-A) in asbestos-exposed workers. Chest 1996;109:467-74.
2. GRENIER B : Décision médicale. Analyse et stratégie de la décision dans la pratique médicale (Seconde édition). Paris : Masson, 1995.
3. COCHRANE GM : Screening. In : Clark THJ, ed. Clinical investigation of respiratory disease. London : Chapman and Hall 1981:117-37.
4. SCHULLER MP, CARRAT F, URBAN T, LEBEAU B : Quels marqueurs tumoraux doit-on utiliser dans les cancers bronchiques primitifs ? Rev Mal Resp 1997;14:3S9-3S11.
5. BRECHOT JM, CHEVRET S, NATAF J et al. : Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer : a prospective study of 116 patients. Eur J Cancer 1997;33:385-91.
6. HUANG MS, JONG SB, TSAI MS et al. : Comparison of cytokeratin fragment 19 (CYFRA21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir Med 1997;91:135-42.
7. PINSON P, JOOS G, WATRIPONT P, BRUSSELLE G, PAUWELS R : Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer. Respiration 1997;64:102-7.
8. SPLF : Recommandations concernant l'utilisation des marqueurs tumoraux sériques dans la prise en charge des cancers bronchiques primitifs. Rev Mal Resp 1997;14:3S5-3S39.
9. NISMAN B, LAFAIR J, HECHING N et al. : Evaluation of tissue polypeptide specific antigen, CYFRA21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma : does the combined use of cytokeratin markers give any additional information ? Cancer 1998;82:1850-9.
10. GRIVAUX M : Intérêt des marqueurs tumoraux pour le dépistage et au moment du diagnostic (hors valeur pronostique et surveillance) des cancers bronchiques primitifs. Rev Mal Resp 1997;14:3S15-3S19.
11. NUORVA K, MAKITARO R, HUHTI E et al. : p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J Respir Crit Care Med 1994;750:528-33.
12. MARION MJ, DE Vivo I, SMITH S, Luo JC, BRANDT-RAUF PW : The molecular epidemiology of occupational carcinogenesis in vinyl chloride exposed workers. Int Arch Occup Environ Health 1996;68:394-8.
13. HANAOKA T, YAMANO Y, KATSUNO N, KAGAWA J, ISHIZU S : Elevated serum levels of pantropic p53 proteins in chromium workers. Scand J Work Environ Health 1997;23:37-40.
14. LUBIN R, SCHLICHTHOLZ B, TEILLAUD JL et al. : p53 antibodies in patients with various types of cancer : assay, identification, and characterization. Clin Cancer Res 1995;1: 1463-9.
15. HEMMINKI K, PARTANEN R, KOSKINEN H, SMITH S, CARNEY W, BRANDT-RAUF PW : The molecular epidemiology of oncoproteins. Serum p53 protein in patients with asbestosis. Chest 1996;109:22S-26S.
16. PARTANEN R, KOSKINEN H, OKSA P et al. : Serum oncoproteins in asbestosis patients. Clin Chem 1995;47:1844-7.
17. LUBIN R, ZALCMAN G, BOUCHET L et al. : Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;7:701-2.
18. HUSGAFVEL-PURSIAINEN K, KANNIO A, OKSA P et al. : Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen 1997;30:224-30.
19. WANG X, CHRISTIANI DC, WIENCKE JK et al. : Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev 1995;4:543-8.
20. QIAO YL, TOCKMAN MS, LI L et al. : A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China. Cancer Epidemiol Biomarkers Prev 1997;6:893-900.
21. CROWELL RE, BELINSKY SA : Genetic changes in lung cancer : potential biomarkers for early detection and prevention. J Lab Clin Med 1997;130:550-7.
22. NELSON HH, WIENCKE JK, GUNN L, WAIN JC, CHRISTIANI DC, KELSEY KT : Chromosome 3p14 alterations in lung cancer : evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998;58:1804-7.
23. GIACCONE G : Oncogenes and antioncogenes in lung tumorigenesis. Chest 1996;109:130S-134S.
24. JACOBSON DR, FISHMAN CL, MILLS NE : Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Ann Oncol 1995;6:S3-8.
25. BRANDT-RAUF PW, LUO JC, CARNEY WP et al. : Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans. Int J Cancer 1994;56:383-6.
26. BRANDT-RAUF PW : The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res 1995;333:203-8.
27. HUWER H, KALWEIT G, ENGEL M, WELTER C, DOOLEY S, GAMS E : Expression of the candidate tumor suppressor gene nm23 in the bronchial system of patients with squamous cell lung cancer. Eur J Cardiothorac Surg 1997;11:206-9.
28. WU D, ZHOU X, YANG G et al. : Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J Immunoassay 1998;19:63-72.
29. PARTANEN R, HEMMINKI K, KOSKINEN H, LUO JC, CARNEY WP, BRANDT-RAUF PW : The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 1994;36:1324-8.
30. BRANDT-RAUF PW, SMITH S, HEMMINKI K et al. : Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 1992;50:881-5.
31. ISSA JP, BAYLIN SB, BELINSKY SA : Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996;56:3655-8.
32. SEKIDO Y, FONG KM, MINNA JD : Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998;1378:F21-59.
33. MULSHINE JL, SCOTT F : Molecular markers in early cancer detection. New screening tools. Chest 1995;107:280S-286S.
34. MULSHINE JL, SCOTT F, ZHOU J, AVIS I, VOS M. TRESTON AM : Recent molecular advances in the approach to early lung cancer detection and intervention. Environ Health Perspect 1997;105 Suppl 4:935-9.
35. SIEGFRIED JM : Biology and chemoprevention of lung cancer. Chest 1998;113:40S-45S.
36. BARTSCH H, HIETANEN E : The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996;104 Suppl 3:569-71.
37. SPIVACK SD, FASCO MJ, WALKER VE, KAMINSKY LS : The molecular epidemiology of lung cancer. Crit Rev Toxicol 1997;27:319-65.
38. SHIELDS PG, BOWMAN ED, HARRINGTON AM, DOAN VT, WESTON A : Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 1993;53:3486-92.
39. KATO S, BOWMAN ED, HARRINGTON AM, BLOMEKE B, SHIELDS PG : Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo [see comments] [published erratum appears in J Natl Cancer Inst 1996 Nov 6;88(21) : 1595]. J Natl Cancer Inst 1995;87:902-7.
40. ROJAS M, ALEXANDROV K, CASCORBI I et al. : High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*O/O genotypes. Pharmacogenetics 1998;8:109-18.
41. SCHOKET B, PHILLIPS DH, KOSTIC S, VINCZE I : Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis 1998;19:841-6.
42. OKEY AB : Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990;45:241-98.
43. NELSON DR, KOYMANS L, KAMATAKI T et al. : P450 superfamily : update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
44. Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfeifer AM : Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 1998;34:914-20.
45. GUENGERICH FP, SHIMADA T : Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 1998;400:201-13.
46. LAURENT P, COSME J, PAIRON J : Cytochrome P450 polymorphisms as markers of genetic risk for lung cancer. In : Hirsch A GM, Martin JP, Masse R, ed. Prevention of respiratory diseases. New York : Marcel Dekker Inc., 1993:373-93. Lung Biology in Health and Disease ; vol 68.
47. HUKKANEN J, HAKKOLA J, ANTTILA S et al. : Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450s in human bronchoalveolar macrophages and peripheral blood lymphocytes. Mol Carcinog 1997;20:224-30.
48. OKEY AB, RIDDICK DS, HARPER PA : The Ah receptor : mediator of the toxicity of 2,3, 7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol Lett 1994;70:1-22.
49. SWANSON HI, BRADFIELD CA : The AH-receptor : genetics, structure and function. Pharmacogenetics 1993;3:213-30.
50. KAWAJIRI K, NAKACHI K, IMAI K, YOSHII A, SHINODA N, WATANABE J : Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990;263:131-3.
51. NAKACHI K, IMAI K, HAYASHI S, WATANABE J, KAWAJIRI K : Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991;51:5177-80.
52. HAYASHI S, WATANABE J, NAKACHI K, KAWAJIRI K : Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo) 1991;110:407-11.
53. OKADA T, KAWASHIMA K, FUKUSHI S, MINAKUCHI T, NISHIMURA S : Association between a cytochrome P450 CYPIA1 genotype and incidence of lung cancer. Pharmacogenetics 1994;4:333-40.
54. SUGIMURA H, WAKAI K, GENKA K et al. : Association of Ile462Val (Exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population : further evidence from a case-control study in Okinawa [In Process Citation]. Cancer Epidemiol Biomarkers Prev 1998;7:413-7.
55. DRAKOULIS N, CASCORBI I, BROCKMOLLER J, GROSS CR, ROOTS I : Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer : exon-7 mutation (4889 a to G), and a T to C mutation in the 3'-flanking region. Clin Investig 1994;72:240-8.
56. SUGIMURA H, SUZUKI I, HAMADA GS et al. : Cytochrome P450 1A1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol Biomarkers Prev 1994;3:145-8.
57. SUGIMURA H, HAMADA GS, SUZUKI I et al. : CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil. Pharmacogenetics 1995;5:S145-8.
58. WEDLUND PJ, KIMURA S, GONZALEZ FJ, NEBERT DW : 1462V mutation in the human CYP1A1 gene : lack of correlation with either the Msp I 1.9 kb (M2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent. Pharmacogenetics 1994;4:21-6.
59. RANNUG A, ALEXANDRIE AK, PERSSON I, INGELMAN-SUNDBERG M : Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1 : regulation and toxicological significance. J Occup Environ Med 1995;37:25-36.
60. KIYOHARA C, HIROHATA T, INUTSUKA S : The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 1996;87:18-24.
61. ZHANG ZY, FASCO MJ, HUANG L, GUENGERICH FP, KAMINSKY LS : Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462 : assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996;56:3926-33.
62. PERSSON I, JOHANSSON I, INGELMAN-SUNDBERG M : In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997;231: 227-30.
63. RAUNIO H, HUSGAFVEL-PURSIAINEN K, ANTTILA S, HIETANEN E, HIRVONEN A, PELKONEN O : Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review. Gene 1995;159:113-21.
64. AYESH R, IDLE JR, RITCHIE JC, CROTHERS MJ, HETZEL MR : Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984;312:169-70.
65. CHRISTENSEN PM, GOTZSCHE PC, BROSEN K : The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer : a meta-analysis. Eur J Clin Pharmacol 1997;51:389-93.
66. ROSTAMI-HODJEGAN A, LENNARD MS, WOODS HF, TUCKER GT : Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998;8:227-38.
67. CAPORASO N, DEBAUN MR, ROTHMAN N : Lung cancer and CYP2D6 (the debrisoquine polymorphism) : sources of heterogeneity in the proposed association. Pharmacogenetics 1995;5:8129-34.
68. RAUCY JL, KRANER JC, LASKER JM : Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 1993;23:1-20.
69. UEMATSU F, KIKUCHI H, MOTOMIYA M et al. : Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991;82:254-6.
70. PERSSON I, JOHANSSON I, BERGLING H et al. : Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993;319:207-11.
71. EL-ZEIN R, ZWISCHENBERGER JB, WOOD TG, ABDEL-RAHMAN SZ, BREKELBAUM C, AU WW : Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 1997;381:189-200.
72. KATO S, SHIELDS PG, CAPORASO NE et al. : Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 1992;52:6712-5.
73. HIRVONEN A, HUSGAFVEL-PURSIAINEN K, ANTTILA S, KARJALAINEN A, VAINIO H : The human CYP2E1 gene and lung cancer : DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993;14:85-8.
74. WATANABE J, YANG JP, EGUCHI H et al. : An Rsa I polymorphism in the CYP2EI gene does not affect lung cancer risk in a Japanese population. Jpn J Cancer Res 1995;86:245-8.
75. STEPHENS EA, TAYLOR JA, KAPLAN N et al. : Ethnic variation in the CYP2E1 gene : polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994;4:185-92.
76. OYAMA T, KAWAMOTO T, MIZOUE T et al. : Cytochrome P4502E1 polymorphism as a risk factor for lung cancer : in relation to p53 gene mutation. Anticancer Res 1997;17: 583-7.
77. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR : Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996;6:527-33.
78. TSUNEOKA Y, FUKUSHIMA K, MATSUO Y, ICHIKAWA Y, WATANABE Y : Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci 1996;59:1711-5.
79. PETRUZZELLI S, DE FLORA S, BAGNASCO M et al. : Carcinogen metabolism studies in human bronchial and lung parenchymal tissues. Am Rev Respir Dis 1989;140:417-22.
80. SEIDEGARD J, PERO RW, MARKOWITZ MM, ROUSH G, MILLER DG, BEATTIE EJ : Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer : a follow up study. Carcinogenesis 1990;11:33-6.
81. HIRVONEN A, HUSGAFVEL-PURSIAINEN K, ANTTILA S, VAINIO H : The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993;14:1479-81.
82. MCWILLIAMS JE, SANDERSON BJ, HARRIS EL, RICHERT-BOE KE, HENNER WD: Glutathione-S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4:589-94.
83. SMITH CM, KELSEY KT, WIENCKE JK, LEYDEN K, LEVIN S, CHRISTIANI DC : Inherited glutathione-S-transferase deficiency is a risk factor for pulmonary asbestosis. Cancer Epidemiol Biomarkers Prev 1994;3:471-7.
84. KELSEY KT, NELSON HH, WIENCKE JK, SMITH CM, LEVIN S : The glutathione-S-transferase theta and mu deletion polymorphisms in asbestosis. Am J Ind Med 1997;31:274-9.
85. HIRVONEN A, PELIN K, TAMMILEHTO L, KARJALAINEN A, MATTSON K, LINNAINMAA K : Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 1995;55: 2981-3.
86. JAKOBSSON K, RANNUG A, ALEXANDRIE AK, RYLANDER L, ALBIN M, HAGMAR L : Genetic polymorphism for glutathione-S-transferase mu in asbestos cement workers. Occup Environ Med 1994;51:812-6.
87. JAKOBSSON K, RANNUG A, ALEXANDRIE AK, WARHOLM M, RYLANDER L, HAGMAR L : Radiographic changes and lung function in relation to activity of the glutathione transferases theta and mu among asbestos cement workers. Toxicol Lett 1995;77:363-9.
88. HAYASHI S, WATANABE J, KAWAJIRI K : High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 1992;83:866-70.
89. NAKACHI K, IMAI K, HAYASHI S, KAWAJIRI K : Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993;53:2994-9.
90. ALEXANDRIE AK, SUNDBERG MI, SEIDEGARD J, TORNLING G, RANNUG A : Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1 : a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 1994;15:1785-90.
91. KELSEY KT, SPITZ MR, ZUO ZF, WIENCKE JK : Polymorphisms in the glutathione-S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes Control 1997;8:554-9.
92. IKAWA S, UEMATSU F, WATANABE K et al. : Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Pharmacogenetics 1995;5:S154-60.